About Systimmune
Systimmune is a company based in Redmond (United States) founded in 2014. It operates as a B2B. The company has 36 employees. Systimmune offers products and services including Bi-specific Antibodies, Multi-specific Antibodies, and Antibody-Drug Conjugates. Systimmune operates in a competitive market with competitors including Zymeworks, Xilio Therapeutics, Harbour BioMed, Ambrx and Lassen Therapeutics, among others.
- Headquarter Redmond, United States
- Employees 36
- SectorsHealthcare
- Website systimmune.com
- Social Facebook
- Legal Name Systimmune, Inc.
- Employee Count36
Products & Services of Systimmune
Systimmune offers a comprehensive portfolio of products and services, including Bi-specific Antibodies, Multi-specific Antibodies, and Antibody-Drug Conjugates.
Antibodies targeting multiple cancer sites for treatment.
Antibodies designed to enhance immune responses against tumors.
Conjugates delivering drugs directly to cancer cells.
Competitors of Systimmune
Systimmune operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Zymeworks, Xilio Therapeutics, Harbour BioMed, Ambrx and Lassen Therapeutics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| zymeworks.com | 2003 | Vancouver, Canada | $145.97M | 277 | Bi-specific antibodies and antibody-drug conjugates are developed for cancer treatment. | |
| xiliotx.com | 2016 | Waltham, United States | $233M | 72 | Tumor-selective immunotherapies for cancer treatment are developed. | |
| harbourbiomed.com | 2016 | Shanghai, China | $312.8M | – | Antibody therapeutics are developed for immunology and oncology diseases. | |
| ambrx.com | 2003 | San Diego, United States | $345.9M | 79 | Antibody-drug conjugates are developed for cancers and metabolic disorders. | |
| lassentherapeutics.com | 2019 | San Diego, United States | $116M | 6 | Biotherapeutics targeting cancer via interleukin-11 are developed. | |
| leaptx.com | 2011 | Cambridge, United States | $24.68M | 44 | Novel immuno-oncology therapeutics are acquired and developed for clinical advancement. | |
| bioatla.com | 2007 | San Diego, United States | $162.31M | 41 | Immunotherapies for cancer are developed using conditionally active biologics platform. | |
| merus.nl | 2003 | Utrecht, Netherlands | $156.19M | – | Antibody-based drugs for cancer treatment are developed using bispecific engineering. | |
| pharmabcine.com | 2008 | Daejeon, South Korea | $6.34M | – | Monoclonal antibodies are developed for cancer and inflammatory disease treatments. |
Detailed competitors of Systimmune
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Systimmune
Complete news archive for Systimmune
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Systimmune
10 companies that operate in the same segment as Systimmune (Immunology & Cancer Therapeutics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | – | – | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Targeted therapies for cancer treatment are developed. | 2005 | Waltham, Massachusetts, United States | USD 198.29 M | USD 172.35 M | 270 | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 215.5 M | USD 29.62 M | 225 | |
Plasma-based biologics are developed for immune deficiency and infectious diseases. | 2005 | Ramsey, Minnesota, United States | USD 17.55 M | USD 510.17 M | 685 | |
Antibody drugs for cancer treatment are developed. | 2015 | Singapore, Singapore | USD 150 M | – | – | |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | 2003 | United States | USD 171.85 M | USD 102.48 M | 338 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Systimmune
Systimmune was founded in 2014.
Systimmune is headquartered in Redmond, United States. It is registered at Redmond, Washington, United States.
Systimmune has 36 employees.
SystImmune is a biopharmaceutical company based in Redmond, WA, specializing in the development of bi-specific and multi-specific antibodies, as well as antibody-drug conjugates for cancer therapy. They focus on systematic interventions in tumor microenvironments to directly attack tumors and activate the immune system. The company partners with entities like OrbiMed for commercialization and conducts global clinical trials to bring therapeutics to market.
Systimmune's top competitors include Xilio Therapeutics, Ambrx and Harbour BioMed.
Systimmune offers Bi-specific Antibodies, Multi-specific Antibodies, and Antibody-Drug Conjugates.
Systimmune operates through Systimmune, Inc..